Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer

• Status: Completed
• Trial end date: 2020-05-12
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical research study is to learn if hyperthermic intraperitoneal chemotherapy (HIPEC) will help to control the disease in patients with Stage 4 stomach or gastroesophageal cancer. The safety of this treatment will also be studied.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Treatments: Cisplatin; Mitomycin; Mitomycins; Sodium thiosulfate

Criteria

Inclusion Criteria:

1. Age 18 years and above. There will be no upper age restriction.

2. Eastern Cooperative Oncology Group (ECOG) performance status

3. Cytologic or histologic proof of adenocarcinoma of the stomach or gastroesophageal junction.

4. Adequate renal, and bone marrow function: a. Leukocytes >/= 3,000/microL; b. Absolute neutrophil count >/= 1,500/microL; c. Platelets >/= 100,000/Ul; d. Serum creatinine

5. Hepatic function: AST (SGOT)/ALT (SGPT)ULN.

6. Distant Metastatic Disease limited to peritoneum and radiologically occult (not visualized on preoperative imaging to include [Computerized Tomography] CT scan, Ultrasound, [Magnetic Resonance Imaging] MRI, PET/CT): a. Positive peritoneal cytology; b. Carcinomatosis on diagnostic laparoscopy or laparotomy.

7. Completion of preoperative systemic chemotherapy.

Exclusion Criteria:

1. Distant metastatic disease not limited to peritoneum: a. Solid organ metastases (liver, central nervous system, lung).

2. Any distant metastatic disease visualized on preoperative imaging: a. Solid organ metastases; b. Clear radiologic evidence of carcinomatosis.

3. Infections such as pneumonia or wound infections that would preclude protocol therapy.

4. Women with a positive urine or serum pregnancy test are excluded from this study; women of childbearing potential (defined as those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to refrain from breast feeding and practice adequate contraception as specified in the informed consent. Adequate contraception consists of oral contraceptive, implantable contraceptives, injectable contraceptives, a double barrier method, or abstinence.

5. Subjects with unstable angina or New York Heart Association Grade II or greater congestive heart failure.

6. Subjects deemed unable to comply with study and/or follow-up procedures.

7. Subjects with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity.